News
When Sarah told her elderly mother about what she had found, she was horrified to hear that James had also been sexually ...
CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...
The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...
The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug Blenrep as a combination treatment, ...
The Cambridge site of an international biotechnology company will cease manufacturing, leaving 150 people without a job.
1d
GlobalData on MSNGSK’s Blenrep combos approved for multiple myeloma in EUThe combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including ...
Explore more
GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults ...
GSK (GSK) stock in focus as the company secures EU approval for Blenrep combo therapies targeting the blood cancer multiple ...
A global biopharmaceutical company headquartered in London announced the layoffs of 150 Massachusetts employees last week.
Alector’s 71% drop prompts a fresh look at its valuation, financials, and pipeline to gauge recovery prospects amid lingering risks. Read why ALEC stock is a hold.
However, yesterday GSK announced that the FDA has extended the review period for Blenrep to give the agency time to review ...
Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results